Other Clinical Trial - Early Switch Maintenance vs Delayed Second-line

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Squamous Non-small Cell Lung Cancer

Clinical Trial Details

NCT number	NCT03542461
Study type	Interventional
Source	Gruppo Oncologico Italiano di Ricerca Clinica
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 25, 2017
Completion date	January 31, 2023

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT04073537` - Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer	Phase 3
	Completed	`NCT03717155` - Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC	Phase 2
	Terminated	`NCT02204345` - A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology	Phase 1/Phase 2
	Terminated	`NCT01911325` - Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients	Phase 1
	Withdrawn	`NCT02924233` - Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer	Phase 1/Phase 2
	Withdrawn	`NCT03319316` - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)	Phase 2
	Completed	`NCT04552535` - A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
	Completed	`NCT01763788` - A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
	Not yet recruiting	`NCT05879484` - Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS	Phase 1/Phase 2
	Completed	`NCT02367794` - A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]	Phase 3
	Recruiting	`NCT04149691` - Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies	Phase 1
	Recruiting	`NCT05243355` - Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC	Phase 2
	Completed	`NCT03366480` - A Study to Assess the Efficacy and Safety of ABTL0812	Phase 1/Phase 2
	Not yet recruiting	`NCT04266730` - Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab	Phase 1
	Terminated	`NCT02109016` - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations	Phase 2
	Completed	`NCT02106546` - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	Phase 3
	No longer available	`NCT02475382` - Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen